Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-29 2:41 pm Sale |
2025-06-30 | 13G | Sutro Biopharma, Inc. STRO |
The Vanguard Group | 4,115,250 4.870% |
-79,822 (-1.90%) |
Filing History |
| 2025-07-16 7:02 pm Sale |
2025-06-30 | 13G | Sutro Biopharma, Inc. STRO |
BlackRock Inc. BLK |
2,092,281 2.500% |
-4,051,327 (-65.94%) |
Filing History |
| 2025-06-30 4:36 pm Purchase |
2025-06-27 | 13G | Sutro Biopharma, Inc. STRO |
Integrated Core Strategies (US) LLC | 4,717,215 5.600% |
3,348,194 (+244.57%) |
Filing History |
| 2025-05-15 11:39 am Purchase |
2025-03-31 | 13G | Sutro Biopharma, Inc. STRO |
Kynam Capital Management LP | 5,441,447 6.440% |
5,441,447 (New Position) |
Filing History |
| 2025-04-17 09:35 am Purchase |
2025-03-31 | 13G | Sutro Biopharma, Inc. STRO |
BlackRock Inc. BLK |
6,143,608 7.300% |
319,686 (+5.49%) |
Filing History |
| 2025-04-04 4:32 pm Purchase |
2025-03-28 | 13G | Sutro Biopharma, Inc. STRO |
RA Capital Management, L.P. | 4,434,637 5.300% |
4,434,637 (New Position) |
Filing History |
| 2024-11-14 7:54 pm Sale |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
Point72 Asset Management, L.P. | 2,997,453 3.700% |
-2,935,455 (-49.48%) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,347,946 (Position Closed) |
Filing History |
| 2024-11-13 4:30 pm Sale |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
Rubric Capital Management LP | 0 0.000% |
-3,344,810 (Position Closed) |
Filing History |
| 2024-11-12 5:46 pm Unchanged |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
The Vanguard Group | 4,195,072 5.110% |
0 (Unchanged) |
Filing History |
| 2024-11-12 09:34 am Purchase |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
Adage Capital Management, L.P. | 2,250,132 2.750% |
2,250,132 (New Position) |
Filing History |
| 2024-11-04 4:07 pm Sale |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
Integrated Core Strategies (US) LLC | 2,031,745 2.500% |
-1,420,080 (-41.14%) |
Filing History |
| 2024-11-04 2:09 pm Purchase |
2024-09-30 | 13G | Sutro Biopharma, Inc. STRO |
The Vanguard Group | 4,195,072 5.110% |
4,195,072 (New Position) |
Filing History |
| 2024-04-05 4:05 pm Purchase |
2024-04-04 | 13G | Sutro Biopharma, Inc. STRO |
Point72 Asset Management, L.P. | 5,932,908 7.900% |
5,932,908 (New Position) |
Filing History |
| 2024-02-13 12:16 pm Purchase |
2023-12-31 | 13G | Sutro Biopharma, Inc. STRO |
SUVRETTA CAPITAL MANAGEMENT LLC | 5,778,188 9.500% |
213,089 (+3.83%) |
Filing History |
| 2024-02-12 06:06 am Purchase |
2023-12-31 | 13G | Sutro Biopharma, Inc. STRO |
Rubric Capital Management LP | 3,344,810 5.490% |
132,938 (+4.14%) |
Filing History |
| 2024-02-07 07:56 am Purchase |
2023-12-31 | 13G | Sutro Biopharma, Inc. STRO |
ADAGE CAPITAL PARTNERS GP L.L.C. | 4,467,796 7.330% |
918,476 (+25.88%) |
Filing History |
| 2024-01-24 5:23 pm Purchase |
2023-12-31 | 13G | Sutro Biopharma, Inc. STRO |
BlackRock Inc. BLK |
5,823,922 9.600% |
963,782 (+19.83%) |
Filing History |
| 2024-01-17 4:54 pm Purchase |
2024-01-10 | 13G | Sutro Biopharma, Inc. STRO |
Integrated Core Strategies (US) LLC | 3,451,825 5.700% |
3,451,825 (New Position) |
Filing History |
| 2023-10-10 4:52 pm Purchase |
2023-09-28 | 13G | Sutro Biopharma, Inc. STRO |
ADAGE CAPITAL PARTNERS GP L.L.C. | 3,549,320 5.860% |
3,549,320 (New Position) |
Filing History |